Védie Anne-Laure, Ezzedine Khaled, Amazan Emmanuelle, Boralevi Franck, Milpied Brigitte, Taïeb Alain, Seneschal Julien
Department of Dermatology, National Reference Centre for Rare Skin Disorders, Saint-André Hospital, 33000 Bordeaux, France.
Acta Derm Venereol. 2016 Aug 23;96(6):802-6. doi: 10.2340/00015555-2389.
Data regarding systemic therapies in the management of atopic dermatitis are limited. The aim of this study was to provide evidence for the efficacy and tolerance of systemic immunosuppressive treatments for moderate-to-severe adult atopic dermatitis. A single-centre retrospective study was conducted. A total of 54 patients were prescribed systemic treatments between 2000 and 2014. Of these, 28 received methotrexate and 55.6% were considered as responders based on Physician's Global Assessment, 17 received azathioprine (37.5% responders), 43 received cyclosporin A (65.9% responders) and 7 received a combination therapy with methotrexate and azathioprine (57.1% responders). These treatments were well-tolerated overall and few adverse events required discontinuation of treatment. Combination therapy associating methotrexate and azathioprine appears to be a promising treatment for patients who fail to respond to conventional monotherapies.
